



A New Treatment for Methamphetamine Use Disorder

OVERDOSE RATES ARE INCREASING ACROSS THE U.S.

Methamphetamine use disorder (MUD) continues to impact the lives of individuals, families, and communities, with rates of methamphetamine overdose rising throughout the United States. Provisional 12-month counts of overdose deaths involving psychostimulants in the United States doubled from the 12-months ending in October 2019 compared to the 12-months ending in October 2021.¹ **Increase in overdose rates highlight the need for treatment of MUD. Medication treatment options for MUD are sorely needed.**

1. Centers for Disease Control and Prevention. (n.d.). *NVSS Vital Statistics Rapid Release: Provisional Drug Overdose Death Counts*. Retrieved March 25, 2022, from <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>

EXTENDED RELEASE BUPROPION AND INJECTABLE NALTREXONE (XR-NTX) CAN HELP

The ADAPT-2 Clinical Trial examined the use of extended-release (ER) bupropion plus extended-release, injectable naltrexone to treat MUD. Among adults with MUD, the response among participants who received treatment was higher than the placebo group, including low attrition, high adherence to trial treatment regimen, reduced cravings and depression symptoms, increased quality of life, and improvement in recovery.²

2. Trivedi, M. H., Walker, R., Ling, W., Dela Cruz, A., Sharma, G., Carmody, T., Ghitz, U. E., Wahle, A., Kim, M., Shores-Wilson, K., Sparenborg, S., Coffin, P., Schmitz, J., Wiest, K., Bart, G., Sonne, S. C., Wakhlu, S., Rush, A. J., Nunes, E. V., & Shoptaw, S. (2021). Bupropion and Naltrexone in Methamphetamine Use Disorder. *The New England Journal of Medicine*, 384(2), 140–153. <https://doi.org/10.1056/NEJMoa2020214>

LEARN MORE ABOUT THIS STUDY AND IMPLICATIONS FOR CLINICAL PRACTICE



The NEW ENGLAND JOURNAL of MEDICINE



ACCESS FULL TEXT ARTICLE >>



LISTEN VIA PODCAST >>

IN COLLABORATION WITH



National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN) Dissemination Initiative

UTSouthwestern O'Donnell Brain Institute



Funded by the National Institute on Drug Abuse and others; ADAPT-2 ClinicalTrials.gov number, NCT03078075

Disclaimer: This resource was funded in part with federal funds from the National Institute on Drug Abuse, Center for the Clinical Trials Network Dissemination Initiative (contract # 75N95020C00028RFP). The content was developed by experts and researchers and does not necessarily reflect the official position of the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. government. This information should not be considered a substitute for legal counsel or individualized patient care and treatment decisions.